Skip to main content

ASCO GU 2020 key clinical trial overviews

Prostate cancer

CHHiP

CHHiP is a phase 3 trial of hypofractionated versus conventional radiotherapy for localized prostate cancer – the researchers will present the 8-year outcomes.

Thursday, February 13

STOMP

The STOMP investigators will present the 5-year results from this trial of metastasis-directed therapy in men with oligometastatic recurrent prostate cancer.

Thursday, February 13

KEYNOTE-199

The KEYNOTE-199 trial seeks to establish a role for PD-1 inhibition in the treatment of metastatic castration-resistant prostate cancer.

Thursday, February 13

Bladder cancer/urothelial carcinoma

NIMBUS

Is a reduced number of BCG infusions noninferior to the standard number in patients with non-muscle invasive bladder cancer? The NIMBUS researchers seek to answer this question.

Friday, February 14

ATLAS

The ATLAS collaborators aim to find out if there is a role for PARP inhibition in the treatment of locally advanced or metastatic urothelial carcinoma.

Friday, February 14

Trial of nadofaragene firadenovec

This is a phase 3 trial of the novel gene therapy nadofaragene firadenovec in BCG-unresponsive patients with non-muscle invasive bladder cancer.

Friday, February 14

Kidney cancer

NIVES

The NIVES study is investigating the efficacy of concomitant nivolumab and stereotactic body radiotherapy in the metastatic RCC setting.

Saturday, February 15

RADVAX RCC

What is the effect on metastatic RCC outcomes of combining immunotherapy and stereotactic body radiotherapy? The RADVAX RCC investigators aim to find out.

Saturday, February 15

HIF-2α inhibition in RCC

Investigators will present data from the advanced clear cell RCC cohort of the first-in-human trial of MK-6482, an inhibitor of hypoxia-inducible factor-2α.

Saturday, February 15